On Monday, ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) opened higher 5.40% from the last session, before settling in for the closing price of $0.52. Price fluctuations for IPA have ranged from $0.32 to $2.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 17.44% over the last five years. Company’s average yearly earnings per share was noted 63.25% at the time writing. With a float of $19.97 million, this company’s outstanding shares have now reached $30.29 million.
The firm has a total of 101 workers. Let’s measure their productivity. In terms of profitability, gross margin is 50.27%, operating margin of -55.48%, and the pretax margin is -125.12%.
ImmunoPrecise Antibodies Ltd (IPA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ImmunoPrecise Antibodies Ltd is 19.92%, while institutional ownership is 7.71%.
ImmunoPrecise Antibodies Ltd (IPA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 63.25% per share during the next fiscal year.
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) Trading Performance Indicators
Check out the current performance indicators for ImmunoPrecise Antibodies Ltd (IPA). In the past quarter, the stock posted a quick ratio of 0.85. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.13 in one year’s time.
Technical Analysis of ImmunoPrecise Antibodies Ltd (IPA)
Analysing the last 5-days average volume posted by the [ImmunoPrecise Antibodies Ltd, IPA], we can find that recorded value of 0.54 million was lower than the volume posted last year of 0.72 million. As of the previous 9 days, the stock’s Stochastic %D was 96.11%. Additionally, its Average True Range was 0.05.
During the past 100 days, ImmunoPrecise Antibodies Ltd’s (IPA) raw stochastic average was set at 31.21%, which indicates a significant decrease from 99.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.14% in the past 14 days, which was lower than the 111.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4323, while its 200-day Moving Average is $0.8319. Now, the first resistance to watch is $0.5704. This is followed by the second major resistance level at $0.5928. The third major resistance level sits at $0.6375. If the price goes on to break the first support level at $0.5033, it is likely to go to the next support level at $0.4586. Now, if the price goes above the second support level, the third support stands at $0.4362.
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) Key Stats
There are currently 31,062K shares outstanding in the company with a market cap of 17.02 million. Presently, the company’s annual sales total 18,160 K according to its annual income of -20,130 K. Last quarter, the company’s sales amounted to 4,490 K and its income totaled -1,870 K.
